Hikma Pharmaceuticals (LSE:HIK) is preparing to open up its R&D pipeline to investors from 20 October, giving the market a closer look at a business that delivered a solid first half but has seen its share price give back its post-results gains.
Hikma Pharmaceuticals, the London-listed maker of generic, branded and injectable medicines, has an unusually busy investor calendar over the coming weeks. The group will host the first of three educational seminars on its R&D strategy on 20 October, followed by its scheduled trading update on 5 November. Together, the events are expected to shape sentiment towards a stock that has drifted lower since a positive reaction to its interim figures in early August.
The R&D series, announced on 22 September, will run from October to December. The opening one-hour session will cover group-level R&D activity alongside respiratory, nasal, semi-solid and liquid products. A second session on 24 November will focus on solid oral medicines, and the final session on 16 December will be devoted to injectables, Hikma's largest franchise. The company has made clear that no new financial or trading information will be disclosed during the seminars, which are intended to improve understanding of its pipeline. Hikma has said it aims to devote roughly 5% to 6% of revenue to R&D over time.
A solid first half
The backdrop is a set of interim results published on 6 August that the market received warmly. Revenue for the six months to 30 June rose 4.2% to $1.73 billion, helped by a 15% increase in the Branded business, which is concentrated in the Middle East and North Africa. Core operating profit increased by around 9% at group level, with the Branded division posting a particularly sharp improvement.
Injectables, which serves mainly the US hospital market, saw core operating profit ease as Hikma (LSE:HIK) stepped up sales and marketing spending to build its US commercial platform. Reported pre-tax profit slipped 2.7% to $287 million, reflecting a swing in net financing costs and a $71 million charge linked to amendments to royalty arrangements and the remeasurement of contingent consideration.
Chief executive Said Darwazah, who moved from executive chair to the chief executive role in February as part of a leadership reshuffle, described the period as a solid first half in line with expectations and said the group remained confident in its outlook. Full-year guidance was reiterated, and the interim dividend was lifted 5.6% to 38 US cents a share.
Shares retreat after August rally
The shares jumped around 10% to roughly 1,733p on the day of the results, but they have since lost much of that ground. By early October the stock was changing hands at around 1,575p, broadly in line with the wider pharmaceutical sector's subdued tone. Investors have been weighing pricing pressure in US generics, the cost of Hikma's investment in its injectables franchise and the broader policy debate over drug pricing and tariffs in the United States, which remains its largest market.
Capital returns have offered some support. The $250 million share buyback programme launched in February was well advanced by early August, with the bulk of it completed. The board was also strengthened during the period with the appointment of Tobias Hestler as an independent non-executive director.
What to watch in November
The 5 November trading update will be the next opportunity for management to confirm whether the group remains on course to meet its full-year targets. Investors are likely to focus on the trajectory of Injectables margins as US investment continues, the durability of growth in the Branded business, and any commentary on the Generics division's product launches. The seminar series may also help the market assess the long-term value of Hikma's pipeline, particularly in complex and specialty products.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...